MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2025 International Congress

    Prevalence of Supine Hypertension in Alpha-Synucleinopathies: a Systematic Review and Meta-Analysis

    V. Arca, PR. Lopes, FL. Westphal Filho, F. Mendes Filho, C. Falcão, J. Parmera (São Paulo, Brazil)

    Objective: We aimed to conduct a systematic review and meta-analysis to assess the prevalence of supine hypertension (SH) in α-synucleinopathies. Background: Alpha-synucleinopathies, including Parkinson’s Disease…
  • 2025 International Congress

    Analysis of the Association between SNCA Polymorphisms and the Risk of Multiple System Atrophy

    N. Abramycheva, M. Andreev, L. Karan, I. Minaev, A. Protopopova, A. Protsenko, E. Fedotova, S. Illaroshkin (Moscow, Russian Federation)

    Objective: To assess the impact of twenty-one single nucleotide polymorphisms (SNPs) located in different regulatory regions of the SNCA gene on the risk of developing…
  • 2025 International Congress

    A Phase 2 Study of Risvodetinib in Untreated Parkinson’s Disease

    M. Werner, C. Meyer, E. Mancino, C. Klint, J. Pellecchia, A. Mcgarry, K. Kieburtz, C. Olanow (Atlanta, USA)

    Objective: Risvodetinib was evaluated in a randomized, double-blind, placebo controlled Phase 2 trial at three doses to determine the safety and tolerability in patients with…
  • 2025 International Congress

    Novel Insights into the Association Between Parkinson’s Disease and Constipation: Role of SHMT2 as a Promising Biomarker

    JH. Su, EX. Tao (Shenzhen, China)

    Objective: This study aims to  analyze the shared molecular pathways between Parkinson’s disease (PD) and constipation through integrative bioinformatics methodologies and further validate candidate biomarkers…
  • 2025 International Congress

    Novel Usage of Alpha Synuclein as a Biomarker for Screening Parkinson’s disease at Komfo Anokye Teaching Hospital in Ghana

    YAW. Osei, SF. Sarfo, FAY. Yeboah Agyemang (Kumasi, Ghana)

    Objective: This study aimed to assess the use of alpha-synuclein as a biomarker for PD screening and investigate its correlation with disease severity. Background: The…
  • 2025 International Congress

    Complement C4 Exacerbates Inflammation and Neuronal Damage in Vivo

    W. Zou, Y. Wang, Y. Xia, L. Kou, T. Wang (wuhan, China)

    Objective: To investigate the specific effects of the core complement component C4 on α-synuclein aggregation and neuroinflammation during the pathogenesis of PD. Background: Synucleinopathies are…
  • 2025 International Congress

    Case Report of an 82 Year Old Man with an 18 Year History of REM Sleep Behavior Disorder and Colonic Lewy Pathology

    K. Minemura, A. Kawanami, A. Horita, M. Hara, Y. Saito, S. Murayama, K. Hasegawa (Kanagawa, Japan)

    Objective: To report a case of an 82-year-old man with a long-standing history of REM sleep behavior disorder (RBD) and colonic Lewy pathology without significant…
  • 2025 International Congress

    Alpha Synuclein Seeding Activity Drives Disease Heterogeneity in an Animal Model of Multiple System Atrophy

    A. Shafique, N. Silver, A. Mao, R. Ferry, I. Martinez-Valbuena, J. Watts, G. Kovacs, N. Visanji (Toronto, Canada)

    Objective: To examine the impact of multiple system atrophy (MSA) brain-derived alpha synuclein (αSyn) with diverse seeding activities in an inoculation-based animal model. Background: We…
  • 2025 International Congress

    PADOVA: Topline results from a Phase IIb study of prasinezumab in early-stage Parkinson’s disease participants on stable symptomatic treatment

    T. Nikolcheva, G. Pagano, J. Anzures-Cabrera, T. Simuni, K. Marek, N. Pavese, K. Seppi, F. Stocchi, R. Postuma, N. Pross, A. Monnet, G. Respondek, L. Rutten-Jacobs, V. Schlegel, L. Boak, G. Kerchner, P. Brundin, H. Svoboda, A. Bonni (Basel, Switzerland)

    Objective: To evaluate the effect of prasinezumab on slowing down disease progression in participants with early-stage Parkinson’s disease (PD) on stable symptomatic medication. Background: Prasinezumab…
  • 2025 International Congress

    Monitoring Parkinson’s Disease in the Dental Chair

    J. Schwartz, L. Dibenedetto, P. Engen, V. Ha, B. Killinger, C. Soto, S. Green, A. Naqvi, S. Tomar, M. Shaikh, M. Villanueva, D. Sanchez-Bass, C. Noh, R. Voigt, C. Goetz, A. Keshavarzian (Chicago, USA)

    Objective: Our goal is to bridge the mechanistic knowledge gap on the Microbiota-Gut-Oral-Brain-Axis (MGOBA)’s role in Parkinson’s disease (PD) pathogenesis through a case-control, proof-of-concept, observational…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley